Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-0610||CPI0610||BET Inhibitor (Pan) 32||CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195, PMID: 31729905).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01949883||Phase I||CPI-0610||A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma||Completed||0|
|NCT02986919||Phase II||CPI-0610||Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors||Withdrawn||USA||0|
|NCT02158858||Phase Ib/II||CPI-0610 + Ruxolitinib CPI-0610||A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis||Recruiting||USA | ITA | FRA | DEU | CAN | BEL||3|
|NCT02157636||Phase I||CPI-0610||A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma||Completed||0|